The size of the global zika virus vaccines market is estimated to be growing at a CAGR of 5.4% during the forecast period. As a result, the market is predicted to value USD 22.09 billion by 2026 from USD 16.98 billion in 2021.
The Zika virus (ZIKV), also known as a flavivirus, is a mosquito-borne disease that spreads through mosquito bites, blood transfusions, sexual activity, and from an infected pregnant woman to her baby. The Zika virus, like other mosquito-borne diseases like the Japanese encephalitis virus, West Nile virus, and yellow fever virus, is spread by mosquitoes of the Aedes genus. It can also be passed to the fetus through sexual contact with an infected individual or pregnant woman. After biting a zika-infected person, a mosquito becomes infected with the virus and spreads it to everyone they sting. mRNA, DNA, and inactivated vaccines are among the numerous types of vaccinations available to defend against the Zika virus.
Furthermore, an infected pregnant woman's fetus can be infected with the virus. PCR detects the infection. The rising incidence of the active Zika virus and growing concern about the virus's repercussions have boosted the market for Zika vaccinations and are the key driver of worldwide Zika virus vaccine demand. The increased prevalence of Zika fever is spurring the development of effective vaccinations. Fever, conjunctivitis, rash, muscle and joint pain, and headache are some of the symptoms. Symptoms usually last between three and seven days. The majority of those infected with the Zika virus do not experience any symptoms. There is currently no licensed vaccine to treat the Zika virus. On the other hand, major pharmaceutical companies are working on new vaccinations to combat Zika virus infection. Vaccines will be either medicinal or preventative in nature. The first Zika virus illness outbreak was reported in 2007 on the island of Yap (Federated States of Micronesia).
Y-O-Y growth in the incidence of the Zika virus across the globe, giving special attention to pregnant women, increasing awareness regarding the infection are majorly fuelling the market growth.
The increased investment made by private organizations for research and development, supportive reimbursements from governments, and technological advancements are other major factors driving the global zika virus vaccines market.
Additionally, increasing focus on immunization, increasing healthcare expenditure, disposable income, and the existence of a large population of virus-affected people are expected to favor the global zika virus vaccines market to grow further. Different types of vaccines are developed to protect against viruses, such as mRNA, DNA-based, genetically engineered, and inactivated vaccines. With the rise in zika virus incidences, many pharmaceutical and biotechnology companies are investing in this market. In a very rare case, the zika virus is also transmitted through blood transfusion. In 2016, the World Health Organization (WHO) declared that the major causes of the zika virus were asymptomatic.
The initiatives taken by the government and non-government organizations are anticipated to offer growth opportunities for the global zika virus vaccine market. Also, academic research centers have shown interest in investing and providing vast amounts in developing new drugs and vaccines, which is expected to boost the market growth during the forecast period.
Lack of knowledge in developing new vaccines with the available technological advancements in undeveloped countries is one of the major restraints to the global zika virus vaccine market growth. Furthermore, the vaccines may also cause harmful effects such as neurological problems and others, which hamper the market. In addition, less availability of required resources in rural areas is a challenging factor for the market players.
Impact of COVID-19 on the global zika virus vaccines market:
COVID-19 was declared a global pandemic in 2020. Pregnant women were identified as vulnerable based on previous exposure to similar viral diseases like H1N1 influenza and severe acute respiratory syndrome (SARS) in Asia. Both viruses are dangerous to pregnant women's health, and as recently emerging pathogens, they are plagued by diagnostic, prognostic, and therapeutic ambiguity, posing challenges for both physicians and patients. Another emerging viral concern, the Zika flavivirus, has been overshadowed by the unexpected and widespread outbreak of coronavirus (SARS-CoV-2). In terms of restricted diagnostic capabilities, treatments, and prognostic uncertainty, ZIKA illness and COVID19 are very similar. Both illnesses are linked to a considerable risk of negative consequences for the pregnant woman or the fetus. In vulnerable communities, existing social and economic inequalities exacerbate the risk of ZIKA illness and COVID-19. Even though each pathogen has its own characteristics, there are underlying fundamental principles for recognizing, communicating, and mitigating infection risk. Both viruses are dangerous to pregnant women's health, and as newly emerging pathogens, they are plagued by diagnostic, prognostic, and therapeutic uncertainty, posing difficulties for physicians and patients alike. Considering all these factors, the Zika Virus Vaccine market has had positive growth during the pandemic.
Market Size Available
2020 to 2026
2021 to 2026
By Type, End-User, and Region
Various Analyses Covered
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities
North America, Europe, APAC, Latin America, Middle East & Africa
This research report on the global zika virus vaccines market has been segmented and sub-segmented based on type, end-user, and region.
Zika Virus Vaccines Market - By Type:
Based on type, the therapeutic vaccines segment is anticipated to grow with the fastest CAGR and would significantly contribute to the global market for zika virus vaccines.
Zika Virus Vaccines Market - By End-User:
The hospital segment held the largest share based on the application, and this trend is projected to continue. Hospitalization would be required if the number of people infected with the Zika virus increased. The segment's growth is also projected to be aided by the early availability of new pharmaceuticals in hospitals.
Zika Virus Vaccines Market - By Region:
Geographically, Latin America dominated the worldwide Zika virus vaccine market in 2020, and this trend is projected to continue over the forecast period. The region's supremacy can be ascribed to the rising number of persons infected with the Zika virus in countries like Brazil, Bolivia, and Peru and the presence of key players. The rise in the number of Zika-infected people is expected to spur effective vaccinations to reduce infection rates. This increases the level of preparedness in the event of future Zika outbreaks. As a result, it can boost Zika vaccine demand and provide opportunities for key companies over the forecast period. Zika fever has infected the populations of 69 countries, causing mild disease, and has spread over Central and South America.
During the same time period, Asia Pacific is predicted to grow at a high rate. The development of Zika virus vaccines is aided by the high prevalence of mosquito-borne illness and improved healthcare infrastructure. In addition, the public's growing awareness of the virus's infection is also fueling demand for these vaccines.
KEY MARKET PLAYERS:
Some of the most prominent companies leading the global zika virus vaccines market profiled in this report are Takeda Pharmaceutical Co. Ltd., NewLink Genetics Co., Immunovaccine Inc., GeneOne Life Science Inc., GlaxoSmithKline PLC, Inovio Pharmaceuticals, Inc., Bharat Biotech International Ltd., Hawaii Biotech Inc., and Sanofi S.A.
RECENT MARKET HAPPENINGS:
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1.2 Therapeutic Vaccines
5.1.3 Preventive Vaccines
5.1.4 Y-o-Y Growth Analysis, By Type
5.1.5 Market Attractiveness Analysis, By Type
5.1.6 Market Share Analysis, By Type
5.2.4 Research institutes
5.2.6 Y-o-Y Growth Analysis, By End-user
5.2.7 Market Attractiveness Analysis, By End-user
5.2.8 Market Share Analysis, By End-user
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
188.8.131.52 By Geographical Area
184.108.40.206 By Type
220.127.116.11 By End-user
6.1.4 Market Attractiveness Analysis
18.104.22.168 By Geographical Area
22.214.171.124 By Type
126.96.36.199 By End-user
6.1.5 Market Share Analysis
188.8.131.52 By Geographical Area
184.108.40.206 By Type
220.127.116.11 By End-user
6.2 North America
6.1.2 United States
6.3.6 South Korea
6.5 Latin America
6.4.5 Rest of Latin America
6.6 Middle East & Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Takeda Pharmaceutical Co. Ltd.,
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 NewLink Genetics Co.,
8.3 Immunovaccine Inc.,
8.4 GeneOne Life Science Inc.,
8.5 GlaxoSmithKline plc.,
8.6 ., Inovio Pharmaceuticals, Inc.,
8.7 Bharat Biotech International Ltd.,
8.8 Hawaii Biotech Inc.,
8.9 Sanofi S.A.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures